Biblio Discovery — Demo Discovery Service

8 results for "David Forster"

Showing 1–8 · 0.90 seconds · RSS

  1. Journal Article

    The Redundancy Matrix as a Performance Indicator for Structural Assessment

    David Forster; Malte von Scheven

    Journal of Theoretical, Computational and Applied Mechanics (2025) · 2025 · English · DOAJ

    The degree of static indeterminacy and its spatial distribution characterize load-bearing structures independent of a specific load case. The redundancy matrix stores the distribution of the static indeterminacy on its main diagonal, and thereby offers the possibility to use this property for the…

  2. Journal Article

    Immune Checkpoint Inhibition in Head and Neck Cancer

    Martin David Forster; Michael-John Devlin

    Frontiers in Oncology, Vol. 8 · 2018 · English · DOAJ Scopus

    Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where…

  3. Journal Article

    Informed consent in cluster randomised trials: a guide for the perplexed

    Monica Taljaard; Cory E Goldstein; Hayden P Nix et al.

    BMJ Open, Vol. 11 No. 9 · 2021 · English · DOAJ Scopus

    In a cluster randomised trial (CRT), intact groups—such as communities, clinics or schools—are randomised to the study intervention or control conditions. The issue of informed consent in CRTs has been particularly challenging for researchers and research ethics committees. Some argue that cluster…

  4. Journal Article Full text

    Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Roy S. Herbst; Edward B. Garon; Dong‐Wan Kim et al.

    Journal of Thoracic Oncology · 2021 · English · OpenAlex Scopus

    INTRODUCTION: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy and safety follow-up for the…

  5. Journal Article Full text

    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

    Roy S. Herbst; Edward B. Garon; Dong‐Wan Kim et al.

    Journal of Clinical Oncology · 2020 · English · OpenAlex Scopus

    PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report KEYNOTE-010…

  6. Journal Article Full text

    Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study

    Alvina Grace Lai; Laura Pasea; Amitava Banerjee et al.

    BMJ Open · 2020 · English · OpenAlex Scopus

    OBJECTIVES: To estimate the impact of the COVID-19 pandemic on cancer care services and overall (direct and indirect) excess deaths in people with cancer. METHODS: We employed near real-time weekly data on cancer care to determine the adverse effect of the pandemic on cancer services. We also used…

  7. Journal Article Full text

    Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    Adrian Gerold Sacher; Patricia A. LoRusso; Manish R. Patel et al.

    New England Journal of Medicine · 2023 · English · OpenAlex Scopus

    Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS…

  8. Journal Article Full text

    The evolution of lung cancer and impact of subclonal selection in TRACERx

    Alexander M. Frankell; Michelle Dietzen; Maise Al Bakir et al.

    Nature · 2023 · English · OpenAlex Scopus

    . Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the…